Dr. Tony Holohan:

I will supplement that. That number, which may be 100,000 - a figure I would not dispute - will be very heterogeneous as the Deputy knows. It will be important for individuals in that group, some of whom have specific reasons for being immunocompromised, to also talk to their individual clinician. Many of them are under the care of expert hospital-based clinicians in that regard. Vaccination for people who are immunocompromised is an ongoing question that arises on a clinical level for the individual, often more so than as a public health measure generally. As Dr. Glynn said, that advice is already there and the HSE is in the course of that. We will give the Deputy an update on that and what the actual progress is on the numbers.

On the question of antivirals, work is under way to set out what those pathways of care would be for those people and what role testing would play in that to ensure that the people, often those in the higher risk groups, who might benefit from the supply of antivirals we may have will be identified quickly in their disease course and given access to those antivirals to match those plans and arrangements that are in place in the UK, as referred to by the Deputy. That work has been undertaken through Dr. Colm Henry's office in the HSE to put those models of care effectively in place and to inform the use antivirals.